Protein-based nanoparticles for therapeutic nucleic acid delivery
Copyright © 2024 Elsevier Ltd. All rights reserved..
To realize the full potential of emerging nucleic acid therapies, there is a need for effective delivery agents to transport cargo to cells of interest. Protein materials exhibit several unique properties, including biodegradability, biocompatibility, ease of functionalization via recombinant and chemical modifications, among other features, which establish a promising basis for therapeutic nucleic acid delivery systems. In this review, we highlight progress made in the use of non-viral protein-based nanoparticles for nucleic acid delivery in vitro and in vivo, while elaborating on key physicochemical properties that have enabled the use of these materials for nanoparticle formulation and drug delivery. To conclude, we comment on the prospects and unresolved challenges associated with the translation of protein-based nucleic acid delivery systems for therapeutic applications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:305 |
|---|---|
| Enthalten in: |
Biomaterials - 305(2024) vom: 05. Feb., Seite 122464 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Eweje, Feyisayo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug delivery |
|---|
| Anmerkungen: |
Date Completed 29.01.2024 Date Revised 18.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biomaterials.2023.122464 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366721879 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366721879 | ||
| 003 | DE-627 | ||
| 005 | 20240218231923.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biomaterials.2023.122464 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1298.xml |
| 035 | |a (DE-627)NLM366721879 | ||
| 035 | |a (NLM)38181574 | ||
| 035 | |a (PII)S0142-9612(23)00472-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Eweje, Feyisayo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Protein-based nanoparticles for therapeutic nucleic acid delivery |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.01.2024 | ||
| 500 | |a Date Revised 18.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Ltd. All rights reserved. | ||
| 520 | |a To realize the full potential of emerging nucleic acid therapies, there is a need for effective delivery agents to transport cargo to cells of interest. Protein materials exhibit several unique properties, including biodegradability, biocompatibility, ease of functionalization via recombinant and chemical modifications, among other features, which establish a promising basis for therapeutic nucleic acid delivery systems. In this review, we highlight progress made in the use of non-viral protein-based nanoparticles for nucleic acid delivery in vitro and in vivo, while elaborating on key physicochemical properties that have enabled the use of these materials for nanoparticle formulation and drug delivery. To conclude, we comment on the prospects and unresolved challenges associated with the translation of protein-based nucleic acid delivery systems for therapeutic applications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Drug delivery | |
| 650 | 4 | |a Gene therapy | |
| 650 | 4 | |a Nanoparticles | |
| 650 | 4 | |a Polypeptides | |
| 650 | 4 | |a Recombinant proteins | |
| 650 | 7 | |a Nucleic Acids |2 NLM | |
| 650 | 7 | |a Proteins |2 NLM | |
| 700 | 1 | |a Walsh, Michelle L |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmad, Kiran |e verfasserin |4 aut | |
| 700 | 1 | |a Ibrahim, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Alrefai, Assma |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jiaxuan |e verfasserin |4 aut | |
| 700 | 1 | |a Chaikof, Elliot L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomaterials |d 1989 |g 305(2024) vom: 05. Feb., Seite 122464 |w (DE-627)NLM012732516 |x 1878-5905 |7 nnns |
| 773 | 1 | 8 | |g volume:305 |g year:2024 |g day:05 |g month:02 |g pages:122464 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biomaterials.2023.122464 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 305 |j 2024 |b 05 |c 02 |h 122464 | ||